Affymax Plunges After Recall of Omontys due to Reactions
This article is for subscribers only.
Affymax Inc. fell as much as 87 percent after the company and partner Takeda Pharmaceutical Co. voluntarily recalled an anemia treatment for kidney dialysis patients after reports of fatal reactions.
Affymax declined to $2.97 at 8:36 a.m. New York time, after dropping to $2.14. The shares of the Palo Alto, California-based company had gained 61 percent in the 12 months through Feb. 22.